Skuteczność i bezpieczeństwo napoju nutraceutycznego na wypadanie włosów u pacjentów stosujących agonistów receptorów GLP-1/GIP
Ocena skuteczności i bezpieczeństwa napoju nutraceutycznego w poprawie wypadania włosów u pacjentów leczonych agonistami receptorów GLP-1/GIP: podwójnie ślepa, randomizowana w stosunku 1:1, kontrolowana placebo próba kliniczna.
The purpose of this clinical trial is to evaluate the efficacy of Olistic© Next Women, a nutraceutical supplement, compared with placebo in improving hair loss in patients undergoing treatment with GLP-1/GIP agonists. This 6-month, randomized, placebo-controlled clinical study investigates whether daily supplementation with Olistic© Next Women leads to significant improvements in hair loss in this patient population. In addition, the study assesses the safety and tolerability of the product throughout the treatment period.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Madrid
-
Madrid, Madrid, Hiszpania, 28006
- Rekrutacyjny
- Grupo Dermatologico Y Estetico Pedro Jaen S.A.
-
Kontakt:
- Leyre Malet, PhD
- Numer telefonu: +34 617862464
- E-mail: info@icmrresearch.com
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Female gender.
- Age >35 years.
- Initiation of treatment with a GLP-1/GIP agonist, or treatment duration < 3 months, as per routine clinical practice in the endocrinology clinic.
- Having signed the participant information sheet and the written informed consent and having been informed of the objective of the study.
- Additional criteria to be included by the client.
Exclusion Criteria:
- Allergy or hypersensitivity to any of the components of the product, or to a product from a similar category to the one being tested.
- Scalp diseases: cicatricial alopecia, alopecia areata, folliculitis decalvans, psoriasis, moderate to severe seborrheic dermatitis, eczema, cancer, etc.
- Women presenting alopecia due to an underlying medical condition (hypothyroidism, anemia, lupus, etc.).
- Pharmacological treatment that may promote the onset of telogen effluvium, initiated within the 3 months prior to study start (e.g., valproic acid, carbamazepine, phenytoin, selective serotonin reuptake inhibitors, oral anticoagulants, retinoids, beta-blockers). Patients who have undergone a dose change of these medications within the same period are also excluded.
- Women with uncontrolled thyroid disorders (hyperthyroidism or hypothyroidism) within the 6 months prior to study initiation.
- Women who have used anti-hair loss products within the last 3 months.
- Women who have initiated or undergone dermatological treatment for hair loss within the last 6 months (minoxidil, finasteride, PRP, mesotherapy, etc.).
- Women who have undergone hair transplantation within the 18 months prior to study initiation.
- Women who have initiated treatment with anxiolytics, antidepressants, amphetamines, ACE inhibitors, or iron within the last 3 months.
- Women who initiated or discontinued hormonal treatment (oral contraceptives, oral or topical hormone replacement therapy, ovarian stimulation) within the 3 months prior to study initiation.
- Pregnant women, postpartum women (within 6 months), breastfeeding women, or women planning to become pregnant during the study period.
- Additional exclusion criteria to be specified by the sponsor.
- Any condition that, in the investigator's opinion, makes participation in the study inappropriate.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie podtrzymujące
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Komparator placebo: Ramię placebo
|
Drinkable formulation consisting of an excipient formulation designed to mimic the organoleptic properties of the active product, reproducing its color and texture while achieving a highly similar taste profile. |
|
Eksperymentalny: Aktywna Grupa Produktowa
|
Drinkable multifactorial food supplement in liquid form, administered once daily in a 25 mL single-dose vial, for a duration of 180 days. The formulation contains a combination of vitamins, minerals, amino acids, plant extracts, and other bioactive compounds designed to support hair growth and scalp health in women +45. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Hair loss
Ramy czasowe: From baseline to Day 180.
|
• Patient Reported Outcome using the Hair Shedding Scale: will assess the degree of hair loss among participants. On the day of the visit, they will be shown an A4 sheet with six ranges: between 1 (minimal shedding) to 6 (copious hair shedding). Ref. Perera E and Sinclair R, 2017 |
From baseline to Day 180.
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Hair loss
Ramy czasowe: From baseline to Day 180.
|
Comb and Wash Test: this test will quantify the number of fallen hairs (outcome number of shed hairs). It will be carried out after refraining from washing the hair for 48 hours and combing the hair for 24 hours. |
From baseline to Day 180.
|
|
Body composition
Ramy czasowe: From baseline to Day 180.
|
Body weight (Kg). Using bioelectrical impedance analysis (BIA) with the Tanita MC-780MA body composition monitor |
From baseline to Day 180.
|
|
Body composition
Ramy czasowe: From baseline to Day 180.
|
BMI (Kg/m2). Using bioelectrical impedance analysis (BIA) with the Tanita MC-780MA body composition monitor |
From baseline to Day 180.
|
|
Body composition
Ramy czasowe: From baseline to Day 180.
|
Fat mass and fat-free mass percentages. Using bioelectrical impedance analysis (BIA) with the Tanita MC-780MA body composition monitor |
From baseline to Day 180.
|
|
Serum iron level
Ramy czasowe: From baseline to Day 180.
|
Serum iron concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Ferritin level
Ramy czasowe: From baseline to Day 180.
|
Serum ferritin concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Transferrin level
Ramy czasowe: From baseline to Day 180.
|
Serum transferrin concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Transferrin saturation
Ramy czasowe: From baseline to Day 180.
|
Transferrin saturation percentage calculated from iron metabolism parameters obtained from blood samples. |
From baseline to Day 180.
|
|
Serum zinc level
Ramy czasowe: From baseline to Day 180.
|
Serum zinc concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
25-hydroxyvitamin D level
Ramy czasowe: From baseline to Day 180.
|
Serum 25-hydroxyvitamin D concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Serum folate level
Ramy czasowe: From baseline to Day 180.
|
Serum folate concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Vitamin B12 level
Ramy czasowe: From baseline to Day 180.
|
Serum vitamin B12 concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Serum albumin level
Ramy czasowe: From baseline to Day 180.
|
Serum albumin concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Thyroid-stimulating hormone (TSH) level
Ramy czasowe: From baseline to Day 180.
|
Serum thyroid-stimulating hormone concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Free thyroxine (free T4) level
Ramy czasowe: From baseline to Day 180.
|
Serum free thyroxine concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Total testosterone level
Ramy czasowe: From baseline to Day 180.
|
Serum total testosterone concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Free testosterone level
Ramy czasowe: From baseline to Day 180.
|
Serum free testosterone concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Dehydroepiandrosterone sulfate (DHEA-S) level
Ramy czasowe: From baseline to Day 180.
|
Serum dehydroepiandrosterone sulfate concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Sex hormone-binding globulin (SHBG) level
Ramy czasowe: From baseline to Day 180.
|
Serum sex hormone-binding globulin concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Fasting glucose level
Ramy czasowe: From baseline to Day 180.
|
Fasting blood glucose concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Glycated hemoglobin (HbA1c)
Ramy czasowe: From baseline to Day 180.
|
Glycated hemoglobin measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Fasting insulin level
Ramy czasowe: From baseline to Day 180.
|
Fasting serum insulin concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
HOMA-IR
Ramy czasowe: From baseline to Day 180.
|
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) calculated from fasting glucose and fasting insulin values. |
From baseline to Day 180.
|
|
Total cholesterol level
Ramy czasowe: From baseline to Day 180.
|
Total cholesterol concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
HDL cholesterol level
Ramy czasowe: From baseline to Day 180.
|
HDL cholesterol concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
LDL cholesterol level
Ramy czasowe: From baseline to Day 180.
|
LDL cholesterol concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Triglyceride level
Ramy czasowe: From baseline to Day 180.
|
Serum triglyceride concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Aspartate aminotransferase (AST) level
Ramy czasowe: From baseline to Day 180.
|
AST concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Alanine aminotransferase (ALT) level
Ramy czasowe: From baseline to Day 180.
|
ALT concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Gamma-glutamyl transferase (GGT) level
Ramy czasowe: From baseline to Day 180.
|
GGT concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Blood urea level
Ramy czasowe: From baseline to Day 180.
|
Blood urea concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Serum creatinine level
Ramy czasowe: From baseline to Day 180.
|
Serum creatinine concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
Inne miary wyników
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Self-assessment questionnaire
Ramy czasowe: From baseline to Day 180.
|
Subject-reported perception of hair condition assessed using a 12-item questionnaire covering perceived hair density, hair shedding, hair strength, hair volume, appearance, and scalp condition. Each item is rated on a 5-point Likert scale ranging from "strongly disagree" to "strongly agree." Higher scores indicate greater perceived improvement in hair and scalp condition. |
From baseline to Day 180.
|
|
Food consumption frequency questionnaire (PREDIMED questionnaire)
Ramy czasowe: From baseline to Day 180.
|
Adherence to the Mediterranean diet assessed using the validated 14-item PREDIMED (Prevención con Dieta Mediterránea) questionnaire. The questionnaire evaluates the frequency of consumption of key food groups and dietary habits characteristic of the Mediterranean diet, including olive oil use, fruit and vegetable intake, legumes, fish, nuts, red meat, sugary beverages, commercial pastries, and wine consumption. Each item is scored 0 or 1, resulting in a total score ranging from 0 to 14, with higher scores indicating greater adherence to the Mediterranean diet. |
From baseline to Day 180.
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- CT-ON-04
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .